Patients with extensive-stage SCLC often respond to induction therapy, but the disease tends to progress rapidly after cytotoxic therapy ends, said Jared Weiss, MD, of the University of North Carolina ...

Roche’s plan to bolster Tecentriq’s position in small cell lung cancer with Jazz Pharmaceuticals’ Zepzelca has paid off. | ...

Still, the therapies’ modest benefit as a maintenance therapy points to how better treatments are needed for small cell lung ...

ZL-1310 earns fast track designation in extensive-stage small cell lung cancer after early trial data showed tumor shrinkage ...

Younger patients with lung cancer are more likely to have mutations that allow for targeted therapies, which can lead to more ...

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

7, 2025 — As many as one ... cells each day to keep the oxygen flowing. For many years, ... Feb. 6, 2025 — Scientists have created a new low-cost, fast response sensor to detect lung cancer ...

The Most Effective Prevention Method for Complications Post Lung Transplant Apr. 22, 2025 — When receiving a lung transplant, one of the most ... that boosts cancer cell metabolism to fuel ...

Teos and GSK were the last to report a new setback in TIGIT targeting for non-small cell lung cancer patients. Read why I am ...

Trastuzumab deruxtecan belongs to a group of antineoplastic drugs known as antibody-drug conjugates (ADCs). This type of ...

The new Lung ... overall survival is used as an endpoint. Instead, several investigators have begun to use MPR, which is tentatively defined as the percentage of patients whose cancer cells ...

The well-established division of primary malignant tumours of the lung into small cell lung cancer ... One other population-based study based on Surveillance, Epidemiology and End Results (SEER) ...